Log in

Relevant bibliographies by topics / Intrinsic subtypes / Journal articles

To see the other types of publications on this topic, follow the link: Intrinsic subtypes.

Journal articles on the topic 'Intrinsic subtypes'

Author: Grafiati

Published: 11 December 2022

Last updated: 19 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Intrinsic subtypes.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kim, Hee Jeong, Beom Seok Ko, Jong Han Yu, et al. "Stage, biology, and age." Journal of Clinical Oncology 31, no. 15_suppl (2013): e11512-e11512. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e11512.

Full text

Abstract:

e11512 Background: Breast cancer subtypes are prognostic and predictive for patients. In this study, prognostic value of TNM stage, intrinsic subtype, and age were compared. Methods: We analyzed results from 7,626 breast cancer patients registered on the Asan medical center database between 1999 and 2009. We compared survival according to the TNM stage, intrinsic subtype using ER, PR, Her2- immunohistochemical staining, and age. Results: Luminal A subtype showed the best survival rates while triple negative subtype showed the worst survival rate amongst intrinsic subtypes. Survival analysis sh

APA, Harvard, Vancouver, ISO, and other styles

2

Canino, Fabio, Federico Piacentini, Claudia Omarini, et al. "Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review." International Journal of Molecular Sciences 23, no. 13 (2022): 7079. http://dx.doi.org/10.3390/ijms23137079.

Full text

Abstract:

Endocrine therapy (ET), associated with CDK 4/6 inhibitors, represents the first choice of treatment for HR+/HER2- metastatic breast cancer (mBC). Primary or secondary endocrine resistance could develop; however validated biomarkers capable of predicting such a conditions are not available. Several studies have shown that HR+/HER2- mBC comprises five intrinsic subtypes. The purpose of this systematic review was to analyze the potential correlations between intrinsic subtype, efficacy of treatment, and patient outcome. Five papers that analyzed the intrinsic subtype with PAM50 assay in patients

APA, Harvard, Vancouver, ISO, and other styles

3

Ivory, Joannie M., Naim Rashid, Paola Zagami, Charles M. Perou, Katherine Elizabeth Reeder-Hayes, and Lisa A. Carey. "Impact of race and age on intrinsic subtype distribution and treatment decisions in metastatic breast cancer: Preliminary analysis of HARMONY (LCCC1829)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 1055. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1055.

Full text

Abstract:

1055 Background: Gene expression profiling (GEP) is used to classify breast cancer (BC) into four intrinsic subtypes: Luminal A (LumA), Luminal B (LumB), HER2-Enriched, and Basal-like. Non-LumA subtypes are associated with poorer outcomes. Studies in early BC show that hormone receptor-positive (HR+)/HER2-negative (HER2-) tumors have a higher frequency of non-LumA subtypes in Black and younger (<50) women. Similarly, triple negative BC, which carries the poorest prognosis and is mostly Basal-like, are overrepresented in Black and younger women. These variations in intrinsic subtype contribu

APA, Harvard, Vancouver, ISO, and other styles

4

Prat, Aleix, Nadia Solovieff, Faye Su, et al. "Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies." Cancer Research 82, no. 4_Supplement (2022): PD2–05—PD2–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-pd2-05.

Full text

Abstract:

Abstract Background: In the ML program, PAM50-based intrinsic subtypes (ie, luminal A [LumA], luminal B [LumB], HER2 enriched [HER2E], and basal-like [Basal]) were found to be prognostic and predictive of ribociclib benefit in ABC (Prat et al. J Clin Oncol. 2021). While ribocliclib demonstrated benefit in all subtypes (except Basal, with a limited sample size), LumB and HER2E derived the largest benefit. However, DNA features of the intrinsic subtypes in the advanced setting remain unknown. Here, we report the results of genomic profiling of baseline circulating tumor DNA (ctDNA) by PAM50-base

APA, Harvard, Vancouver, ISO, and other styles

5

Parker, Joel S., Michael Mullins, Maggie C. U. Cheang, et al. "Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes." Journal of Clinical Oncology 27, no. 8 (2009): 1160–67. http://dx.doi.org/10.1200/jco.2008.18.1370.

Full text

Abstract:

Purpose To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression–based “intrinsic” subtypes luminal A, luminal B, HER2-enriched, and basal-like. Methods A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and an

APA, Harvard, Vancouver, ISO, and other styles

6

Parker, Joel S., Michael Mullins, Maggie C. U. Cheang, et al. "Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes." Journal of Clinical Oncology 41, no. 26 (2023): 4192–99. http://dx.doi.org/10.1200/jco.22.02511.

Full text

Abstract:

PURPOSE To improve on current standards for breast cancer prognosis and prediction of chemotherapy benefit by developing a risk model that incorporates the gene expression–based “intrinsic” subtypes luminal A, luminal B, HER2-enriched, and basal-like. METHODS A 50-gene subtype predictor was developed using microarray and quantitative reverse transcriptase polymerase chain reaction data from 189 prototype samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, and 133 patients were evaluated for prediction of pathologic complete response (pCR) to a taxane and an

APA, Harvard, Vancouver, ISO, and other styles

7

Erdem-Eraslan, Lale, Lonneke A. Gravendeel, Johan de Rooi, et al. "Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951." Journal of Clinical Oncology 31, no. 3 (2013): 328–36. http://dx.doi.org/10.1200/jco.2012.44.1444.

Full text

Abstract:

Purpose Intrinsic glioma subtypes (IGSs) are molecularly similar tumors that can be identified based on unsupervised gene expression analysis. Here, we have evaluated the clinical relevance of these subtypes within European Organisation for Research and Treatment of Cancer (EORTC) 26951, a randomized phase III clinical trial investigating adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglial tumors. Our study includes gene expression profiles of formalin-fixed, paraffin-embedded (FFPE) clinical trial samples. Patients and Methods Gene expression pr

APA, Harvard, Vancouver, ISO, and other styles

8

Kim, Jee Hung, Soong June Bae, Sung Gwe Ahn, et al. "Abstract PO5-02-09: Discordance of the PAM50 intrinsic subtypes with the immunohistochemistry-based subtypes in HER2-negative early breast cancer treated with neoadjuvant chemotherapy." Cancer Research 84, no. 9_Supplement (2024): PO5–02–09—PO5–02–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-02-09.

Full text

Abstract:

Abstract Background The PAM50 (Prosigna Breast Cancer Gene Signature Assay) can be used to assess the expression levels of 50 genes in early breast cancer biopsies, including formalin-fixed paraffin-embedded (FFPE) tissue from human epidermal growth factor receptor 2 (HER2)-negative patients. However, there is currently no practical molecular assay for intrinsic subtype in real-world practice that addresses the problems of cost and run-time. Methods In the phase 2 HER2E-PAM/PAMILIA study (NCT04817540), we prospectively analyzed molecular subtyping through the PAM50 test in low HER2 (HER2 IHC 1

APA, Harvard, Vancouver, ISO, and other styles

9

Kim, S. Rim, Nan Song, Greg Yothers, et al. "Tumor sidedness and intrinsic subtypes in patients with stage II/III colon cancer: Analysis of NSABP C-07 (NRG Oncology)." Journal of Clinical Oncology 35, no. 15_suppl (2017): 3514. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3514.

Full text

Abstract:

3514 Background: The predictive value of tumor sidedness in colorectal cancer is currently of interest especially in metastatic setting for anti-EGFR therapy response. We tested whether intrinsic molecular subtype classification predictive of treatment benefit in stage II/III colon cancer is an independent novel marker in association with tumor sidedness. Methods: All available cases included in the NSABP/NRG C-07 trial for which we had both gene expression data and anatomical data (n=1603) were used to determine the molecular subtypes using the following classifiers; the Colorectal Cancer Ass

APA, Harvard, Vancouver, ISO, and other styles

10

Jenkins, Emily Oldham, Allison Mary Deal, Carey K. Anders, et al. "Breast cancer intrinsic subtypes by PAM50 in older women." Journal of Clinical Oncology 30, no. 15_suppl (2012): 1524. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1524.

Full text

Abstract:

1524 Background: Breast cancer (BC) incidence dramatically increases with age and the number of older BC patients (pts) in the U.S. is rising. Although immunohistochemical (IHC) data confirm that the incidence of luminal BC increases with age while the incidence of triple negative (TN) BC decreases, age-specific data on the frequency of BC subtypes defined by gene expression is limited. We characterized the incidence of BC intrinsic subtypes using gene microarrays according to age. Methods: Data from 2,150 pts were pooled from publicly available microarray datasets to determine the incidence o

APA, Harvard, Vancouver, ISO, and other styles

11

Prat, Aleix, Anwesha Chaudhury, Nadia Solovieff, et al. "Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies." Journal of Clinical Oncology 39, no. 13 (2021): 1458–67. http://dx.doi.org/10.1200/jco.20.02977.

Full text

Abstract:

PURPOSE The prognostic and predictive value of intrinsic subtypes in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer treated with endocrine therapy and ribociclib (RIB) is currently unknown. We evaluated the association of intrinsic subtypes with progression-free survival (PFS) in the MONALEESA trials. METHODS A retrospective and exploratory PAM50-based analysis of tumor samples from the phase III MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials was undertaken. The prognostic relationship of PAM50-based subtypes with PFS and risk of disease p

APA, Harvard, Vancouver, ISO, and other styles

12

Wen, Xin, Yingjiao Yu, Xiwen Yu, et al. "Correlations Between Ultrasonographic Findings of Invasive Lobular Carcinoma of the Breast and Intrinsic Subtypes." Ultraschall in der Medizin - European Journal of Ultrasound 40, no. 06 (2018): 764–70. http://dx.doi.org/10.1055/a-0715-1668.

Full text

Abstract:

Abstract Purpose To analyze the ultrasonographic findings of invasive lobular carcinoma (ILC) of the breast in 360 women and the correlations between the characteristics and the intrinsic subtypes. Materials and Methods We evaluated the imaging findings according to the lexicon of the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). The included ultrasonographic features were shape, orientation, margin, echo pattern, posterior features, calcifications, the vascularity of the masses and the presence of architectural distortions. The associations between those fe

APA, Harvard, Vancouver, ISO, and other styles

13

Liang, Huiying, Xuexi Yang, Lujia Chen, et al. "Heterogeneity of Breast Cancer Associations with Common Genetic Variants inFGFR2according to the Intrinsic Subtypes in Southern Han Chinese Women." BioMed Research International 2015 (2015): 1–9. http://dx.doi.org/10.1155/2015/626948.

Full text

Abstract:

GWAS have identified variation in theFGFR2locus as risk factors for breast cancer. Validation studies, however, have shown inconsistent results by ethnics and pathological characteristics. To further explore this inconsistency and investigate the associations ofFGFR2variants with breast cancer according to intrinsic subtype (Luminal-A, Luminal-B, ER−&PR−&HER2+, and triple negative) among Southern Han Chinese women, we genotyped rs1078806, rs1219648, rs2420946, rs2981579, and rs2981582 polymorphisms in 609 patients and 882 controls. Significant associations with breast cancer risk were

APA, Harvard, Vancouver, ISO, and other styles

14

Shibahara, Takuma, Chisa Wada, Yasuho Yamashita, et al. "Deep learning generates custom-made logistic regression models for explaining how breast cancer subtypes are classified." PLOS ONE 18, no. 5 (2023): e0286072. http://dx.doi.org/10.1371/journal.pone.0286072.

Full text

Abstract:

Differentiating the intrinsic subtypes of breast cancer is crucial for deciding the best treatment strategy. Deep learning can predict the subtypes from genetic information more accurately than conventional statistical methods, but to date, deep learning has not been directly utilized to examine which genes are associated with which subtypes. To clarify the mechanisms embedded in the intrinsic subtypes, we developed an explainable deep learning model called a point-wise linear (PWL) model that generates a custom-made logistic regression for each patient. Logistic regression, which is familiar

APA, Harvard, Vancouver, ISO, and other styles

15

Kovalenko, E. I., and E. V. Artamonova. "‘Inner world’ of luminal HER 2-negative metastatic breast cancer: Efficacy of ribociclib in different intrinsic subtypes." Medical alphabet, no. 17 (October 22, 2023): 22–26. http://dx.doi.org/10.33667/2078-5631-2023-17-22-26.

Full text

Abstract:

The heterogeneity of breast cancer (BC), which determines various clinical scenarios of the disease, is still inaccessible to our understanding. Heterogeneity is based primarily on intrinsic subtypes of breast cancer, determined using genomic tests. Currently, four intrinsic subtypes are generally recognized: luminal A and B, HER-enriched (HER2-E) and basal-like. HER2-E subtype in luminal HER-negative (ER+HER–) breast cancer accounts for 11–22 per cent of cases. The efficacy of a combination of hormone therapy (HT) and the CDK4/6 inhibitor ribociclib in the HER2-E subtype was evaluated in a la

APA, Harvard, Vancouver, ISO, and other styles

16

Lum, Jonathon. "The intrinsic frame of reference and the Dhivehi ‘FIBO’ system." Cognitive Linguistics 32, no. 4 (2021): 703–37. http://dx.doi.org/10.1515/cog-2020-0103.

Full text

Abstract:

Abstract While geocentric and relative frames of reference have figured prominently in the literature on spatial language and cognition, the intrinsic frame of reference has received less attention, though various subtypes of the intrinsic frame have been proposed. This paper presents a revised classification of the intrinsic frame, distinguishing between three subtypes: a ‘direct’ subtype, an ‘object-centered’ subtype and a ‘figure-anchored’ subtype, with a cross-cutting distinction between ‘function-based’ and ‘shape-based’ systems. In addition, the ‘FIBO’ (front = inner, back = outer) syste

APA, Harvard, Vancouver, ISO, and other styles

17

Schagerholm, Caroline, Stephanie Robertson, Emelie Karlsson, Emmanouil Sifakis, and Johan Hartman. "Abstract PO3-16-04: Distribution of intrinsic subtypes in endocrine-resistant and endocrine-sensitive breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO3–16–04—PO3–16–04. http://dx.doi.org/10.1158/1538-7445.sabcs23-po3-16-04.

Full text

Abstract:

Abstract Background Breast cancer (BC) is a heterogeneous disease that can be divided into intrinsic molecular subtypes. Among the four intrinsic subtypes, Luminal A and Luminal B are the most common and associated with the best outcome, whereas HER2-enriched and basal-like are less frequent. Tumors that are estrogen receptor α (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) are mostly found among the luminal subtypes. Despite that patients with ER+/HER2- tumors are offered adjuvant endocrine therapy, around one-third eventually develop endocrine resistan

APA, Harvard, Vancouver, ISO, and other styles

18

Agostinetto, Elisa, Mattia Rediti, Danai Fimereli, et al. "HER2-Low Breast Cancer: Molecular Characteristics and Prognosis." Cancers 13, no. 11 (2021): 2824. http://dx.doi.org/10.3390/cancers13112824.

Full text

Abstract:

Background: We aimed to determine the distribution of intrinsic subtypes within HER2-low breast cancer (BC), and to describe the prognostic impact of HER2-low status on survival outcomes. Methods: This is a retrospective, observational study of primary BC extracted from The Cancer Genome Atlas dataset. We described the distribution of PAM50 intrinsic subtypes within HER2-low BC subtype according to hormonal receptor status (positive (HR+) and negative (HR−)). Secondly, we assessed the impact of HER2-low on survival outcomes (progression-free interval (PFI), disease-free interval (DFI), and ove

APA, Harvard, Vancouver, ISO, and other styles

19

Le Cornet, Charlotte, Audrey Y. Jung, Sabine Behrens, et al. "Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer." JAMA Network Open 8, no. 7 (2025): e2519236. https://doi.org/10.1001/jamanetworkopen.2025.19236.

Full text

Abstract:

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. T

APA, Harvard, Vancouver, ISO, and other styles

20

Reddy, Sandeep K., Tara Elisabeth Seery, and Christopher Szeto. "Results of a fifty-gene breast cancer RNA subtype classifier applied to 167 colorectal cancer (CRC) patients." Journal of Clinical Oncology 38, no. 4_suppl (2020): 20. http://dx.doi.org/10.1200/jco.2020.38.4_suppl.20.

Full text

Abstract:

20 Background: ERBB2 (HER2) is thought to be a target in <10% of CRC patients versus 20% of breast cancers, 15% of gastroesophageal cancers, and 10% of biliary cancers, based on FISH or IHC. Intrinsic molecular subtype is used to classify cancers into distinct biologic subtypes (eg. CMS 1-4 in CRC). A 50-gene qPCR assay (PAM50) identifies 5 intrinsic biological subtypes: luminal A, luminal B, HER2-enriched, basal-like, and normal-like in breast cancer. The HERACLES trial (trastuzumab plus lapatinib) resulted a 32% ORR and median TTP of 5.5 months in heavily pre-pretreated HER2+ CRC patients

APA, Harvard, Vancouver, ISO, and other styles

21

Chism, David D., Jeffrey S. Damrauer, Andrew S. Miller, Matthew I. Milowsky, and William Y. Kim. "BASE47 gene set predictor as an identifier of “basal-like” subtype of urothelial carcinoma of the bladder in African Americans." Journal of Clinical Oncology 32, no. 4_suppl (2014): 300. http://dx.doi.org/10.1200/jco.2014.32.4_suppl.300.

Full text

Abstract:

300 Background: African-Americans [AAs] have a higher cancer-specific mortality when compared to whites with urothelial carcinoma (UC) of the bladder. Recent gene expression studies identified two intrinsic, molecular subsets of high-grade bladder cancer: “luminal” and “basal-like”, which can be accurately classified using the BASE47 gene set predictor. We applied the BASE47 gene set predictor to AA tumors and assessed enrichment for basal-like bladder tumors. Methods: Gene expression data from 179 high-grade, muscle invasive bladder tumors—9 AAs and 170 non-AAs (whites, Asians, and race not d

APA, Harvard, Vancouver, ISO, and other styles

22

Agrawal, Sushma, Punita Lal, Shaleen Kumar, et al. "Pathological response and its effect on survival with neoadjuvant chemotherapy according to intrinsic subtype in locally advanced breast cancers in north India: Is it different from the West?" Journal of Clinical Oncology 32, no. 26_suppl (2014): 90. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.90.

Full text

Abstract:

90 Background: Breast cancer patients commonly present in locally advanced stage (LABC) in our country. We propose to correlate the pathological response to neoadjuvant chemotherapy (NACT) and its impact on survival based on the intrinsic subtypes. Methods: Consecutive patients of LABC who underwent NACT (taxane and or anthracyclines based )followed by definitive surgery and radiotherapy during the period January 2007 to December 2012 were grouped on the basis of intrinsic subtypes (Luminal A, Luminal B, Her-2 Type, Basal). The pathological response to NACT in tumour as well as axillary nodes

APA, Harvard, Vancouver, ISO, and other styles

23

Shaoxian, Tang, Yu Baohua, Xu Xiaoli, et al. "Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes." Journal of Clinical Pathology 70, no. 11 (2017): 926–34. http://dx.doi.org/10.1136/jclinpath-2016-204137.

Full text

Abstract:

AimsGATA-binding protein 3 (GATA3) is a sensitive and relatively specific marker in breast and urothelial carcinomas. Its diagnostic utility in primary and metastatic breast cancers has been explored and confirmed. However, the relationship between GATA3 expression and different breast carcinoma intrinsic subtypes has not been specifically defined in the literature despite a few reports with a small number of cases. The aim of the current investigation is to clarify GATA3 expression among different histological subtypes and surrogate molecular breast carcinoma subtypes in a large series of cas

APA, Harvard, Vancouver, ISO, and other styles

24

Ahmed, Talal, Mark Carty, Kaveri Nadhamuni, and Raphael Pelossof. "Abstract PO5-24-03: Breast cancer intrinsic subtypes predict outcomes in primary and metastatic samples." Cancer Research 84, no. 9_Supplement (2024): PO5–24–03—PO5–24–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-24-03.

Full text

Abstract:

Abstract Background: The prognostic and predictive value of the PAM50 intrinsic subtypes, namely Luminal A, Luminal B, Her2, and Basal-like subtypes, is well-studied in primary as well as metastatic breast cancer settings. Prosigna has emerged as a rapid PAM50 subtype predictor based on the NanoString nCounter assay. However, assay reproducibility across various RNASeq or qRT-PCR platforms can be challenging, especially when applying the predictor on metastatic breast cancer tumors. Here, we used SpinAdapt to create an intrinsic subtype predictor that works on RNA sequencing data, and validate

APA, Harvard, Vancouver, ISO, and other styles

25

Dings, Mark P. G., Amber P. Zalm, Marjolein F. Lansbergen, et al. "Abstract 4008: Transcriptomic signatures in esophageal adenocarcinoma define distinct subtypes with therapeutic relevance." Cancer Research 82, no. 12_Supplement (2022): 4008. http://dx.doi.org/10.1158/1538-7445.am2022-4008.

Full text

Abstract:

Abstract Background & Aims: Esophageal cancer is the fifth most common solid cancer globally, and esophageal adenocarcinoma (EAC) is the predominant histological subtype in the western world. Patients often present at an advanced stage and overall-5-year survival rates are less than 15%. In many patients, the response to neoadjuvant therapy is encouraging at first, but most will develop metastatic disease several years later. Recently, we observed plasticity along the epithelial-to-mesenchymal (EMT) axis in EAC tumor cells upon therapeutic pressure. The last decade has seen the discovery o

APA, Harvard, Vancouver, ISO, and other styles

26

Karam, Julie, Paul Rejto, Jadwiga R. Bienkowska, Xinmeng J. Mu, and Whijae Roh. "Abstract 4543: Identification of tumor-specific breast cancer expression subtypes and subtype-specific drug response prediction." Cancer Research 83, no. 7_Supplement (2023): 4543. http://dx.doi.org/10.1158/1538-7445.am2023-4543.

Full text

Abstract:

Abstract Breast cancer is a complex disease with a high degree of inter-tumor heterogeneity. Subtyping the disease and identifying the genomic features driving these subtypes are critical for precision oncology for breast cancer. With increasing availability of single cell RNA-seq data and deconvolution methods, there is unmet need for identifying novel tumor-intrinsic subtypes based on deconvoluted tumor-specific expression profiles as well as novel bulk tumor subtypes based on bulk RNA-seq data. Drug response prediction based on tumor-intrinsic subtypes can be also potentially more robust th

APA, Harvard, Vancouver, ISO, and other styles

27

McConkey, David J., Woonyoung Choi, Andrea Ochoa, and Colin P. N. Dinney. "Intrinsic subtypes and bladder cancer metastasis." Asian Journal of Urology 3, no. 4 (2016): 260–67. http://dx.doi.org/10.1016/j.ajur.2016.09.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Lee, Jieun, Keun Seok Lee, Joohyuk Sohn, et al. "Impacts of subtypes on clinical feature and outcome of male breast cancer." Journal of Clinical Oncology 40, no. 16_suppl (2022): e12528-e12528. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e12528.

Full text

Abstract:

e12528 Background: The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry (IHC), their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea. Methods: We retrospectively analyzed clinical data of 248 MBC patients 18 institutions across the country from January 1995 to July 2016. Results: The median age of MBC patients was 63 years (range: 2

APA, Harvard, Vancouver, ISO, and other styles

29

Armañanzas, Ruben, Bo Liang, Saloni Kanakia, Jeffrey J. Bazarian, and Leslie S. Prichep. "Identification of Concussion Subtypes Based on Intrinsic Brain Activity." JAMA Network Open 7, no. 2 (2024): e2355910. http://dx.doi.org/10.1001/jamanetworkopen.2023.55910.

Full text

Abstract:

ImportanceThe identification of brain activity–based concussion subtypes at time of injury has the potential to advance the understanding of concussion pathophysiology and to optimize treatment planning and outcomes.ObjectiveTo investigate the presence of intrinsic brain activity–based concussion subtypes, defined as distinct resting state quantitative electroencephalography (qEEG) profiles, at the time of injury.Design, Setting, and ParticipantsIn this retrospective, multicenter (9 US universities and high schools and 4 US clinical sites) cohort study, participants aged 13 to 70 years with mi

APA, Harvard, Vancouver, ISO, and other styles

30

Masuda, Hiroko, Keith A. Baggerly, Ying Wang, et al. "Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer." Journal of Clinical Oncology 31, no. 15_suppl (2013): 1005. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1005.

Full text

Abstract:

1005 Background: By gene profiling, Lehmann et al. (J Clin Invest 121:2750-2767, 2011) reported that triple-negative breast cancer (TNBC) can be classified into 6 clusters—basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR)—plus an unstable (UNS) cluster. While it is clear that patients with TNBC differently respond to chemotherapy, the clinical relevance of these molecular TNBC subtypes is unknown. Methods: We qualitatively reproduced the Lehmann et al. experiments using Affymetrix CEL files from the

APA, Harvard, Vancouver, ISO, and other styles

31

Jørgensen, Charlotte Levin Tykjær, Anna-Maria Larsson, Carina Forsare, et al. "PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications." Cancers 13, no. 7 (2021): 1592. http://dx.doi.org/10.3390/cancers13071592.

Full text

Abstract:

Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors (PTs) and metastases to outline subtype changes and their prognostic role. Methods: RNA was isolated from PTs, lymph node metastases (LNMs), and distant metastases (DMs) in metastatic breast cancer patients (n = 140) included in a prospective study (NCT01322893). Gene expression analyses were performed using the Breast Cancer 360 (BC360) assay from Nano-String. The subtype shifts were ev

APA, Harvard, Vancouver, ISO, and other styles

32

Carey, Lisa, Nadia Solovieff, Fabrice André, et al. "Abstract GS2-00: Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer." Cancer Research 82, no. 4_Supplement (2022): GS2–00—GS2–00. http://dx.doi.org/10.1158/1538-7445.sabcs21-gs2-00.

Full text

Abstract:

Abstract Background: The MONALEESA (ML)-2, -3, and -7 trials have shown a significant benefit in overall survival (OS) with ribociclib (RIB) + endocrine therapy (ET) over placebo (PBO) + ET in HR+/HER2− advanced breast cancer. HR+ breast cancer is a clinically and biologically heterogeneous disease, with identified intrinsic subtypes that vary in incidence, survival rate, and response to treatment. In a pooled analysis of the ML studies, patients with both luminal and HER2-enriched (HER2E) subtypes exhibited a consistent progression-free survival benefit with RIB + ET. The HER2E subtype (RIB,

APA, Harvard, Vancouver, ISO, and other styles

33

Coiro, Saverio, Elisa Gasparini, Giuseppe Falco, et al. "Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience." Diagnostics 11, no. 12 (2021): 2249. http://dx.doi.org/10.3390/diagnostics11122249.

Full text

Abstract:

The adoption of neoadjuvant chemotherapy (NACT) for breast cancer (BC) is increasing. The need to repeat the biomarkers on a residual tumor after NACT is still a matter of debate. We verified estrogen receptors (ER), progesterone receptors (PR), Ki67 and human epidermal growth factor receptor 2 (HER2) status changes impact in a retrospective monocentric series of 265 BCs undergoing NACT. All biomarkers changed with an overall tendency toward a reduced expression. Changes in PR and Ki67 were statistically significant (p = 0.001). Ki67 changed in 114/265 (43.0%) cases, PR in 44/265 (16.6%), ER i

APA, Harvard, Vancouver, ISO, and other styles

34

Gumowska, Magdalena, Joanna Mączewska, Piotr Prostko, Katarzyna Roszkowska-Purska, and Katarzyna Dobruch-Sobczak. "Is There a Correlation between Multiparametric Assessment in Ultrasound and Intrinsic Subtype of Breast Cancer?" Journal of Clinical Medicine 10, no. 22 (2021): 5394. http://dx.doi.org/10.3390/jcm10225394.

Full text

Abstract:

Molecular profile of breast cancer provides information about its biological activity, prognosis and treatment strategies. The purpose of our study was to investigate the correlation between ultrasound features and molecular subtypes of breast cancer. From June 2019 to December 2019, 86 patients (median age 57 years; range 32–88) with 102 breast cancer tumors were included in the study. The molecular subtypes were classified into five types: luminal A (LA), luminal B without HER2 overexpression (LB HER2−), luminal B with HER2 overexpression (LB HER2+), human epidermal growth factor receptor 2

APA, Harvard, Vancouver, ISO, and other styles

35

Torres-de la Roche, Luz Angela, Isabell Steljes, Wolfgang Janni, Thomas W. P. Friedl, and Rudy Leon De Wilde. "The Association between Obesity and Premenopausal Breast Cancer According to Intrinsic Subtypes – a Systematic Review." Geburtshilfe und Frauenheilkunde 80, no. 06 (2020): 601–10. http://dx.doi.org/10.1055/a-1170-5004.

Full text

Abstract:

Abstract Introduction Obesity is a well-established risk factor for postmenopausal hormone-receptor positive breast cancer. The relationship between premenopausal breast cancer intrinsic subtypes and obesity is not completely elucidated; therefore, this systematic review was conducted to give an overview about the existing evidence. Methods This review followed the PRISMA Statement for Systematic Reviews and Meta-analyses. Full electronic search was conducted in PubMed and Orbis for articles published in English between January 2008 and June 2018. The literature search was performed in June 20

APA, Harvard, Vancouver, ISO, and other styles

36

Prat, Aleix, Tomás Pascual, and Barbara Adamo. "Intrinsic molecular subtypes of HER2+ breast cancer." Oncotarget 8, no. 43 (2017): 73362–63. http://dx.doi.org/10.18632/oncotarget.20629.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kim, Rim S., Patrick G. Gavin, Soonmyung Paik, et al. "Tumor stroma percentage (TSP) and intrinsic subtypes in stage II/III colon cancer: NRG Oncology/NSABP C-07 trial." Journal of Clinical Oncology 37, no. 15_suppl (2019): e15075-e15075. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15075.

Full text

Abstract:

e15075 Background: Recent molecular subtype studies of colorectal cancer (CRC) have identified various genomic signatures. Regardless of the variety of studies, poor prognosis is associated with stem-like or mesenchymal subtypes, which are largely contributed by stromal cells or cancer-associated fibroblasts (CAF) and are driven by transforming growth factor-beta (TGF-ß) signaling. Tumor stroma percentage (TSP) in CRC morphologically evaluated on H&E slides has been reported as an independent prognostic parameter in stage II/III colon cancer patients (pts). We tested the association of TSP

APA, Harvard, Vancouver, ISO, and other styles

38

Simon, Iris, Paul Roepman, Andreas Schlicker, et al. "Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT)." Journal of Clinical Oncology 31, no. 4_suppl (2013): 333. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.333.

Full text

Abstract:

333 Background: Unbiased genome-wide analyses of gene expression patterns have been successfully used for the molecular classification of breast cancer into subtypes that have clear relevance for prognosis and development of treatment plans. For colorectal cancer (CRC), however, a molecular classification is still missing. Methods: Using gene expression data of 188 stage I-IV colorectal cancer (CRC) patients, a molecular subtype classification was developed. The classifier was validated in 543 stage II and III patients and the subtypes were analyzed for correlation to clinical information, mut

APA, Harvard, Vancouver, ISO, and other styles

39

Shiraishi, K., K. Nakagawa, H. Yamashita, A. Terahara, K. Ohtomo, and T. Yamaguchi. "Long-term results of breast-conservation therapy for Japanese women classified according to intrinsic subtype." Journal of Clinical Oncology 27, no. 15_suppl (2009): e11578-e11578. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e11578.

Full text

Abstract:

e11578 Background: Microarray analysis has identified breast cancer subtypes with distinct gene expression profiles according to the estrogen receptor (ER) and the human epidermal growth factor 2 (HER2) expression. The luminal subtypes (ER-positive) appear to be associated with the better prognosis, whereas the basal and HER2 subgroups tend to have worse recurrence rates. The impact of intrinsic subtype for Japanese women with early-stage invasive breast cancer on prognosis is unknown. The purpose of this study is to address whether breast cancer subtype is associated with recurrence among Jap

APA, Harvard, Vancouver, ISO, and other styles

40

Li, James, Julian McClellan, Haoyu Zhang, Guimin Gao, and Dezheng Huo. "Abstract PO5-09-03: Multi-tissue transcriptome-wide association studies identified genes for intrinsic subtypes of breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO5–09–03—PO5–09–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-09-03.

Full text

Abstract:

Abstract Background: Though several genome-wide association studies (GWAS) of breast cancer (BC) have identified common variants which differ between intrinsic subtypes, the genes through which these variants act through to impact BC risk have not been fully established. Furthermore, transcriptome-wide association studies (TWAS) have thus far been primarily employed to identify genes associated with overall BC risk, while overlooking how the influence of common variation on gene expression may contribute to subtype-specific differences. Methods: In this study, we performed two complementary mu

APA, Harvard, Vancouver, ISO, and other styles

41

Nawaz P. N., Shoaib, Nikhil Sebastian, Raja T., et al. "Molecular classification of breast cancer using IHC markers: experience from a tertiary cancer center in south India." International Journal of Research in Medical Sciences 11, no. 10 (2023): 3729–33. http://dx.doi.org/10.18203/2320-6012.ijrms20233027.

Full text

Abstract:

Background: Breast cancer is a very heterogeneous disease. Molecular or intrinsic subtypes of breast cancer are based on the gene expression profiling. Doing gene expression profiling in each case is practically difficult. So most of the labs depend on immunohistochemistry to classify breast tumors into various molecular-like subtypes. In this study, we have used immune histochemistry to classify tumors into various subtypes. Methods: We have retrospectively collected the data of breast cancer patients treated at Apollo Cancer Center, Chennai, in whom ER, PR, HER 2 Neu and Ki 67 were done, and

APA, Harvard, Vancouver, ISO, and other styles

42

Amansyah, Fitran, Prihantono Prihantono, Firdaus Hamid, Salman Ardi Syamsu, John Pieter Jr., and Muhammad Faruk. "The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer." Breast Disease 43, no. 1 (2024): 71–78. http://dx.doi.org/10.3233/bd-249000.

Full text

Abstract:

BACKGROUND: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients. METHODS: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examinatio

APA, Harvard, Vancouver, ISO, and other styles

43

Oishi, Koji, Kazunori Nakajima, and Jun Motoyama. "Activation of Sonic Hedgehog Signaling Promotes Differentiation of Cortical Layer 4 Neurons via Regulation of Their Cell Positioning." Journal of Developmental Biology 10, no. 4 (2022): 50. http://dx.doi.org/10.3390/jdb10040050.

Full text

Abstract:

Neuronal subtypes in the mammalian cerebral cortex are determined by both intrinsic and extrinsic mechanisms during development. However, the extrinsic cues that are involved in this process remain largely unknown. Here, we investigated the role of sonic hedgehog (Shh) in glutamatergic cortical subtype specification. We found that E14.5-born, but not E15.5-born, neurons with elevated Shh expression frequently differentiated into layer 4 subtypes as judged by the cell positioning and molecular identity. We further found that this effect was achieved indirectly through the regulation of cell pos

APA, Harvard, Vancouver, ISO, and other styles

44

Denkert, Carsten, Krishna Rachakonda, Martin Filipits, et al. "Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B." Journal of Clinical Oncology 42, no. 16_suppl (2024): 566. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.566.

Full text

Abstract:

566 Background: The concept of intrinsic subtyping has been an important step for understanding of breast cancer (BC) as a heterogenous disease. However, these subtypes are not adapted to therapy-induced molecular plasticity. We have evaluated a high-risk luminal BC clinical trial cohort to identify new additional adaptive BC subtypes based on molecular alterations induced during neoadjuvant chemotherapy (NACT). Methods: A total of 1250 ER+/HER2- BC patients (pts) with residual disease after NACT and increased risk (CPS-EG score of ≥3 or 2 with ypN+) were randomized into the PENELOPE-B (NCT018

APA, Harvard, Vancouver, ISO, and other styles

45

Stefanovic, Stefan, Thomas Deutsch, Ralph Wirtz, et al. "Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells." Cancers 11, no. 3 (2019): 342. http://dx.doi.org/10.3390/cancers11030342.

Full text

Abstract:

The presence of circulating tumor cells (CTCs), detected as a form of liquid biopsy is associated with poor survival in both early and metastatic breast cancer. Monitoring tumor biology based on intrinsic subtypes delivers treatment-relevant information on the heterogeneity or biomarker conversion between primary and metastatic tumors. This study aimed to correlate the change of the apoptotic and intact CTC counts with mRNA-assessed intrinsic subtype change. Thirty-four breast cancer patients with available triplets of primary tumors, distant metastasis biopsies and data on intact and apoptoti

APA, Harvard, Vancouver, ISO, and other styles

46

Kazerooni, Anahita Fathi, Adam Kraya, Komal S. Rathi, et al. "IMG-10. IMAGING SUBTYPES OF PEDIATRIC LOW-GRADE GLIOMA ARE ASSOCIATED WITH DISTINCT MOLECULAR CHARACTERISTICS." Neuro-Oncology 26, Supplement_4 (2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.347.

Full text

Abstract:

Abstract BACKGROUND Pediatric low-grade gliomas (pLGGs) have diverse molecular subtypes with distinct prognoses, necessitating personalized treatments. We aimed to determine whether radiomic features of pLGGs co-segregate with molecular subtypes, establishing a proof-of-concept that distinct molecular aberrations could manifest in differentiable imaging features. METHODS Leveraging radiomic, genomic, and transcriptomic data from 201 pLGG patients from the Children’s Brain Tumor Network (CBTN), we identified imaging-based pLGG subtypes through their radiophenotypes. This involved investigating

APA, Harvard, Vancouver, ISO, and other styles

47

Santos, Cristina, Rebeca Sanz-Pamplona, Ernest Nadal, et al. "Intrinsic cancer subtypes-next steps into personalized medicine." Cellular Oncology 38, no. 1 (2015): 3–16. http://dx.doi.org/10.1007/s13402-014-0203-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Paula, Bruno de, Susanne Crocamo, Carlos Augusto Moreira de Sousa, Priscila Valverde, Fabiana Rezende, and Eliana Abdelhay. "Triple-Negative Breast Cancer Subclassified by Immunohistochemistry: Correlation with Clinical and Pathological Outcomes in Patients Receiving Neoadjuvant Chemotherapy." International Journal of Molecular Sciences 25, no. 11 (2024): 5825. http://dx.doi.org/10.3390/ijms25115825.

Full text

Abstract:

The intrinsic subtype of triple-negative breast cancer (TNBC) is based on genomic evaluation. In this study, we report the survival and pathological complete response (pCR) rates of TNBC patients subtyped by IHC and treated with neoadjuvant chemotherapy (NACT). A retrospective cohort of 187 TNBC patients who received NACT between 2008 and 2017 was used, and IHC subtyping was performed on biopsy specimens before chemotherapy. The subtyping revealed predominantly basal-like tumors (IHC-BL, 61%), followed by basal-like immune-suppressed tumors (IHC-BLIS, 31%), mesenchymal tumors (12.5%), luminal

APA, Harvard, Vancouver, ISO, and other styles

49

Woldesonbet, Zelalem Desalegn, Meron Yohannes, Martin Porsch, et al. "Abstract B074: Intrinsic subtypes in Ethiopian breast cancer patients: Implications for better care." Clinical Cancer Research 30, no. 21_Supplement (2024): B074. http://dx.doi.org/10.1158/1557-3265.liqbiop24-b074.

Full text

Abstract:

Abstract Objective: The recent development of multi-gene assays for gene expression profiling has contributed significantly to the understanding of the clinically and biologically heterogeneous breast cancer (BC) disease. PAM50 is one of these assays used to stratify BC patients and individualize treatment. The present study was conducted to characterize PAM50-based intrinsic subtypes among Ethiopian BC patients. Patients and methods: Formalin-fixed paraffin- embedded tissues were collected from 334 BC patients who attended five different Ethiopian health facilities. All samples were assessed

APA, Harvard, Vancouver, ISO, and other styles

50

Cheang, Maggie Chon U., Miguel Martin, Torsten O. Nielsen, et al. "Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG." Journal of Clinical Oncology 30, no. 15_suppl (2012): 1008. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.1008.

Full text

Abstract:

1008 Background: Most TNBC trials focusing on biology of the basal-like subtype (BLBC) allow borderline (1-10% staining) estrogen receptor (ER) and progesterone receptor (PgR) expression by immunohistochemistry (IHC); however the optimal ER and PgR cut points to enrich for non-luminal subtypes has not been studied. In this study,we compared quantitative ER/PgR status with gene expression-based intrinsic subtype in order to determine if borderline cases should be included in TNBC trials. Methods: ER, PgR, and HER2 status was determined by central review of tumors collected from three phase III

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!